Figure 1.

(a) DprE1 in the biosynthesis of arabinan in the cell wall of Mtb and the presence of inhibitor leading to interruption in arabinan biosynthesis. (b) Novel drug candidates: non-covalent inhibitors of DprE1 demonstrating IC₅₀ values at early stages. (c) Scaffold-hopping strategy: polar tail (in circle iii), hydrophobic head (in circle ii)), and lipophilic trunk (in circle i). Exploration of novel ligands through the chemical structures of DprE1 inhibitor (TCA-1). (d) The DprE1 assay measures DprE1 activity using a fluorescence-based assay that involves the reduction of resazurin to resorufin, while DprE1 catalyses the oxidation of GGPR to GGPX using FAD as the cofactor.